Clinical-stage biopharmaceutical company GRI Bio Inc. (GRI) is under the spotlight ahead of a key clinical milestone, the release of topline data from its fully enrolled Phase 2a trial evaluating GRI-0621 for idiopathic pulmonary fibrosis or IPF. This data, expected in the third quarter of 2025, will offer a more complete picture of the drug's safety, biomarker impact, and potential efficacy over the full 12-week treatment period.
The anticipation follows the release of encouraging interim data from its ongoing Phase 2a clinical trial of GRI-0621.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.